Skip to main content
Clinical Trials/JPRN-UMIN000050063
JPRN-UMIN000050063
Completed
未知

Pharmacokinetic study by single intake of the test food (pilot study) - Pharmacokinetic study by single intake of the test food (pilot study)

Other0 sites25 target enrollmentJanuary 21, 2023
ConditionsHealthy adults

Overview

Phase
未知
Intervention
Not specified
Conditions
Healthy adults
Sponsor
Other
Enrollment
25
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 21, 2023
End Date
March 31, 2023
Last Updated
2 years ago
Study Type
Interventional
Sex
Male

Investigators

Sponsor
Other

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) Subjects with a serious medical history, or with a history of disorders of the digestive system, circulatory system (e.g., heart failure), endocrine system, etc. Subjects who have been judged to be inappropriate for the study by the principal investigator. 2\) Subjects who have a history of gastrointestinal resection surgery, excluding appendectomy. 3\) Subjects who are currently taking medication or being treated by a physician. 4\) Subjects who must be scheduled to receive medical treatment or medication during the study period. 5\) Subjects who plan to consume health foods or supplements other than the food under study after consent. 6\) Subjects who are unable to consume the test food due to preference or allergy. Subjects who may have allergies related to the test food. 7\) Heavy drinkers of alcohol and heavy smokers. 8\) Subjects who have difficulty in taking blood samples. 9\) Subjects who donated blood over 200mL in the past 4 weeks or over 400mL in the past 12 weeks. 10\) Subjects who currently or will be participating in another clinical research study during the study period. 11\) Subjects who have irregular sleep or eating habits due to night work or insomnia. 12\) Subjects who are engaged in strenuous physical activity. 13\) Subjects judged as unsuitable for the study by the responsible doctor for other reasons.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in AdolescentsType 2 Diabetes MellitusTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2014-004993-40-Outside-EU/EEAMerck & Co., Inc.35
Active, not recruiting
Phase 1
PK Study in Adolescents and Young Adults Treated with GlucocorticoidsOsteoporosisMedDRA version: 18.1Level: PTClassification code 10031282Term: OsteoporosisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Body processes [G] - Bones and nerves physological processes [G11]
EUCTR2012-003414-14-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as19
Active, not recruiting
Not Applicable
PK Study in Adolescents with Glucocorticoid-Induced Osteoporosis
EUCTR2012-003414-14-Outside-EU/EEAMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as16
Active, not recruiting
Phase 1
PK Study in Adolescents and Young Adults Treated with Glucocorticoids
EUCTR2012-003414-14-ITMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.24
Active, not recruiting
Phase 1
PK Study in Adolescents and Young Adults Treated with GlucocorticoidsOsteoporosisMedDRA version: 18.1Level: PTClassification code 10031282Term: OsteoporosisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Body processes [G] - Bones and nerves physological processes [G11]
EUCTR2012-003414-14-FIMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as19